ClinicalTrials.gov
public full text
Public Domain
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults. The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART#915726
- HIV Vaccine Study in HIV Positive Patients#1152279
- Daclizumab to Treat HIV-Infected Patients#830283
- A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients#873814
- HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs#852024
Record · ID 1100604
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive